Literature DB >> 1579407

Apolipoprotein A-I, A-II, B, C-II, and C-III in children with insulin-dependent diabetes mellitus.

N al Muhtaseb1, A al Yousuf, J S Bajaj.   

Abstract

This study was conducted to determine whether changes in the levels of plasma apolipoproteins (apo) A-I, A-II, B, C-II, and C-III, along with cholesterol and triglycerides, could provide additional information on these parameters in relation to the control of glycemia. Plasma and lipoprotein lipids and apolipoprotein levels were measured in 123 insulin-dependent diabetic children (4- to 12-years-old), classified into good, fair, and poor diabetic control based on HbA1c and fructosamine levels, and in 62 comparable healthy controls. Total cholesterol, very low density lipoprotein cholesterol, and low density lipoprotein cholesterol, as well as total triglycerides, very low density lipoprotein, low density lipoprotein, and high density lipoprotein (HDL) triglycerides, and apo B and apo C-III were increased significantly in children with fair and poor diabetic control. While in diabetic children with good control, only very low density lipoprotein cholesterol was elevated significantly compared with healthy control subjects. Conversely, the levels of cholesterol in HDL, HDL2, HDL3, and apo A-I were decreased significantly in the three diabetic groups, but apo A-II and apo C-II did not change. We conclude that in children with insulin-dependent diabetes mellitus, abnormalities in plasma lipid, lipoprotein, and apolipoprotein levels occur, the extent of which depends on the degree (extent) of glycemic control (the poorer the control the more substantial the abnormality). We suggest that measurement of apo C-III level along with apo B and apo A-I in these patients may be a sensitive indicator to alterations in glycemic control.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1579407

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice.

Authors:  T Ebara; K Conde; Y Kako; Y Liu; Y Xu; R Ramakrishnan; I J Goldberg; N S Shachter
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Circulating lipids and glycaemic control in insulin dependent diabetic children.

Authors:  K Azad; J M Parkin; S Court; M F Laker; K G Alberti
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

3.  Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes.

Authors:  Lisa Juntti-Berggren; Essam Refai; Ioulia Appelskog; Mats Andersson; Gabriela Imreh; Nancy Dekki; Sabine Uhles; Lina Yu; William J Griffiths; Sergei Zaitsev; Ingo Leibiger; Shao-Nian Yang; Gunilla Olivecrona; Hans Jörnvall; Per-Olof Berggren
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

4.  Serum lipid profiles and glycemic control in adolescents and young adults with type 1 diabetes mellitus.

Authors:  Shin-Hee Kim; In-Ah Jung; Yeon Jin Jeon; Won Kyoung Cho; Kyoung Soon Cho; So Hyun Park; Min Ho Jung; Byoung Kyu Suh
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-12-31

5.  Lipid Profile in Relation to Glycemic Control in Type 1 Diabetes Children and Adolescents in Bangladesh.

Authors:  Bedowra Zabeen; Ana Margarida Balsa; Nasreen Islam; Mukta Parveen; Jebun Nahar; Kishwar Azad
Journal:  Indian J Endocrinol Metab       Date:  2018 Jan-Feb

Review 6.  Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle.

Authors:  Ismael Valladolid-Acebes; Per-Olof Berggren; Lisa Juntti-Berggren
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

7.  Temporal sequence of blood lipids and insulin resistance in perimenopausal women: the study of women's health across the nation.

Authors:  Wenhao Yu; Guangshuai Zhou; Bingbing Fan; Chaonan Gao; Chunxia Li; Mengke Wei; Jiali Lv; Li He; Guoshuang Feng; Tao Zhang
Journal:  BMJ Open Diabetes Res Care       Date:  2022-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.